Abstract
We described a 70 years old patient with pericardial effusion due to adenocarcinoma of the lung, in whom gefitinib, which is an oral selective inhibitor of the epidermal growth factor receptor of tyrosine kinase, demonstrated a marked antitumor effect. We recommend possible consideration of a treatment with gefitinib for female patients with pericarditis carcinomatosa due to lung adenocarcinoma, even if they have a poor performance status and are not indicated for other intensive therapy.
MeSH terms
-
Adenocarcinoma / complications
-
Adenocarcinoma / drug therapy*
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Epidermal Growth Factor / antagonists & inhibitors*
-
Female
-
Gefitinib
-
Humans
-
Lung Neoplasms / complications
-
Lung Neoplasms / drug therapy*
-
Pericardial Effusion / diagnosis
-
Pericardial Effusion / etiology*
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Quinazolines / therapeutic use*
Substances
-
Antineoplastic Agents
-
Quinazolines
-
Epidermal Growth Factor
-
Protein-Tyrosine Kinases
-
Gefitinib